Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma

Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma

Bibliographic Details
Main Authors:	Yuri Sakaguchi, Takaya Komori, Megumi Aoki, Atsushi Otsuka, Kenji Kabashima, Shigeto Matsushita
Format:	Article
Language:	English
Published:	Medical Journals Sweden 2020-11-01
Series:	Acta Dermato-Venereologica
Online Access:	https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3681

Similar Items

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
by: Alexander N Shoushtari, et al.
Published: (2021-10-01)

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab
by: S. Morteza Seyed Jafari, et al.
Published: (2020-10-01)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
by: Constance Reichert, et al.
Published: (2023-08-01)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
by: Nethanel Asher, et al.
Published: (2020-08-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
by: Jason Zhang, et al.
Published: (2019-12-01)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
by: Krisztian Homicsko, et al.
Published: (2022-05-01)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
by: Takeshi Fukumoto, et al.
Published: (2022-08-01)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
by: Andrew Hantel, et al.
Published: (2018-07-01)

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
by: Jesper Geert Pedersen, et al.
Published: (2022-07-01)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
by: Bianca Gautron Moura, et al.
Published: (2022-12-01)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
by: Ronen Stoff, et al.
Published: (2022-11-01)

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
by: Vincent T. Ma, et al.
Published: (2022-07-01)

Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma
by: Matthew J. Rabinowitz, et al.
Published: (2021-01-01)

Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab
by: Karima Khimani, et al.
Published: (2022-03-01)

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
by: Taku Fujimura, et al.
Published: (2018-01-01)

Erosive Lichen Planus on the Extremities During Combination Therapy with Nivolumab and Radiation: A Second Case Report
by: Kosuke Katsuo, et al.
Published: (2020-03-01)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
by: Lukas Kraehenbuehl, et al.
Published: (2022-05-01)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
by: Lucía Vázquez-Montero, et al.
Published: (2023-06-01)

Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy
by: Thilo Gambichler, et al.
Published: (2018-10-01)

Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab
by: Remberto Burgos, et al.
Published: (2022-01-01)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
by: M. N. Khagazheeva, et al.
Published: (2022-06-01)

Urticaria multiforme following nivolumab-ipilimumab therapy
by: Sonal Muzumdar, et al.
Published: (2020-06-01)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022-08-01)

563 A case series of neoadjuvant ipilimumab and nivolumab in 2 patients with locoregional mucosal melanoma
by: Daniel J Olson, et al.
Published: (2023-11-01)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
by: W. J. Mullally, et al.
Published: (2022-04-01)

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
by: Marin A. McDonald, et al.
Published: (2018-05-01)

Photosensitive rash induced by nivolumab
by: Francisco J. Navarro-Triviño, et al.
Published: (2022-09-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
by: Dahlia Fedele, et al.
Published: (2024-01-01)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01)

Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab
by: Félix Pham, et al.
Published: (2022-10-01)

Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience
by: Renata Pacholczak-Madej, et al.
Published: (2022-10-01)

Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma
by: Ravi Sutaria, et al.
Published: (2019-07-01)

Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
by: Hélène Salaün, et al.
Published: (2022-12-01)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Sadanori Furudate, et al.
Published: (2016-10-01)

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
by: Giuseppe Minniti, et al.
Published: (2019-04-01)

Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
by: Adnan Kilani, et al.
Published: (2023-01-01)

Results of combined nivolumab and ipilimumab therapy in patients with cancer
by: M. A. Lyadova, et al.
Published: (2021-12-01)

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab
by: Shelby L Kubicki, et al.
Published: (2018-10-01)

Adverse events induced by nivolumab and ipilimumab combination regimens
by: Kohei Somekawa, et al.
Published: (2022-02-01)